Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

Targeted Inhibition of Calpain Reduces Myocardial Hypertrophy and Fibrosis in Mouse Models of Type 1 Diabetes

Targeted Inhibition of Calpain Reduces Myocardial Hypertrophy and Fibrosis in Mouse Models of... OBJECTIVERecently we have shown that calpain-1 activation contributes to cardiomyocyte apoptosis induced by hyperglycemia. This study was undertaken to investigate whether targeted disruption of calpain would reduce myocardial hypertrophy and fibrosis in mouse models of type 1 diabetes.RESEARCH DESIGN AND METHODSDiabetes in mice was induced by injection of streptozotocin (STZ), and OVE26 mice were also used as a type 1 diabetic model. The function of calpain was genetically manipulated by cardiomyocyte-specific knockout Capn4 in mice and the use of calpastatin transgenic mice. Myocardial hypertrophy and fibrosis were investigated 2 and 5 months after STZ injection or in OVE26 diabetic mice at the age of 5 months. Cultured isolated adult mouse cardiac fibroblast cells were also investigated under high glucose conditions.RESULTSCalpain activity, cardiomyocyte cross-sectional areas, and myocardial collagen deposition were significantly increased in both STZ-induced and OVE26 diabetic hearts, and these were accompanied by elevated expression of hypertrophic and fibrotic collagen genes. Deficiency of Capn4 or overexpression of calpastatin reduced myocardial hypertrophy and fibrosis in both diabetic models, leading to the improvement of myocardial function. These effects were associated with a normalization of the nuclear factor of activated T-cell nuclear factor-κB and matrix metalloproteinase (MMP) activities in diabetic hearts. In cultured cardiac fibroblasts, high glucose–induced proliferation and MMP activities were prevented by calpain inhibition.CONCLUSIONSMyocardial hypertrophy and fibrosis in diabetic mice are attenuated by reduction of calpain function. Thus targeted inhibition of calpain represents a potential novel therapeutic strategy for reversing diabetic cardiomyopathy. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Diabetes Pubmed Central

Targeted Inhibition of Calpain Reduces Myocardial Hypertrophy and Fibrosis in Mouse Models of Type 1 Diabetes

Download PDF
10 pages

Loading next page...
 
/lp/pubmed-central/targeted-inhibition-of-calpain-reduces-myocardial-hypertrophy-and-5iQtSo6CfK

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Pubmed Central
Copyright
© 2011 by the American Diabetes Association.
ISSN
0012-1797
eISSN
1939-327X
DOI
10.2337/db10-1333
Publisher site
See Article on Publisher Site

Abstract

OBJECTIVERecently we have shown that calpain-1 activation contributes to cardiomyocyte apoptosis induced by hyperglycemia. This study was undertaken to investigate whether targeted disruption of calpain would reduce myocardial hypertrophy and fibrosis in mouse models of type 1 diabetes.RESEARCH DESIGN AND METHODSDiabetes in mice was induced by injection of streptozotocin (STZ), and OVE26 mice were also used as a type 1 diabetic model. The function of calpain was genetically manipulated by cardiomyocyte-specific knockout Capn4 in mice and the use of calpastatin transgenic mice. Myocardial hypertrophy and fibrosis were investigated 2 and 5 months after STZ injection or in OVE26 diabetic mice at the age of 5 months. Cultured isolated adult mouse cardiac fibroblast cells were also investigated under high glucose conditions.RESULTSCalpain activity, cardiomyocyte cross-sectional areas, and myocardial collagen deposition were significantly increased in both STZ-induced and OVE26 diabetic hearts, and these were accompanied by elevated expression of hypertrophic and fibrotic collagen genes. Deficiency of Capn4 or overexpression of calpastatin reduced myocardial hypertrophy and fibrosis in both diabetic models, leading to the improvement of myocardial function. These effects were associated with a normalization of the nuclear factor of activated T-cell nuclear factor-κB and matrix metalloproteinase (MMP) activities in diabetic hearts. In cultured cardiac fibroblasts, high glucose–induced proliferation and MMP activities were prevented by calpain inhibition.CONCLUSIONSMyocardial hypertrophy and fibrosis in diabetic mice are attenuated by reduction of calpain function. Thus targeted inhibition of calpain represents a potential novel therapeutic strategy for reversing diabetic cardiomyopathy.

Journal

Diabetes – Pubmed Central

Published: Oct 17, 2011

References

  • BoudinaSAbelED. Diabetic cardiomyopathy revisited. Circulation 2007;115:3213–322317592090
  • Di FilippoCMarfellaRCuzzocreaS. Hyperglycemia in streptozotocin-induced diabetic rat increases infarct size associated with low levels of myocardial HO-1 during ischemia/reperfusion. Diabetes 2005;54:803–81015734859
  • GreerJJWareDPLeferDJ. Myocardial infarction and heart failure in the db/db diabetic mouse. Am J Physiol Heart Circ Physiol 2006;290:H146–H15316113078
  • SchrammTKGislasonGHKøberL. Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people. Circulation 2008;117:1945–195418378618
  • FangZYPrinsJBMarwickTH. Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr Rev 2004;25:543–56715294881
  • PoornimaIGParikhPShannonRP. Diabetic cardiomyopathy: the search for a unifying hypothesis. Circ Res 2006;98:596–60516543510
  • GollDEThompsonVFLiHWeiWCongJ. The calpain system. Physiol Rev 2003;83:731–80112843408
  • HannaRACampbellRLDaviesPL. Calcium-bound structure of calpain and its mechanism of inhibition by calpastatin. Nature 2008;456:409–41219020623
  • SuzukiKHataSKawabataYSorimachiH. Structure, activation, and biology of calpain. Diabetes 2004;53(Suppl. 1):S12–S1814749260
  • ArthurJSElceJSHegadornCWilliamsKGreerPA. Disruption of the murine calpain small subunit gene, Capn4: calpain is essential for embryonic development but not for cell growth and division. Mol Cell Biol 2000;20:4474–448110825211
  • PeltierJBellocqAPerezJ. Calpain activation and secretion promote glomerular injury in experimental glomerulonephritis: evidence from calpastatin-transgenic mice. J Am Soc Nephrol 2006;17:3415–342317082241
  • LiXLiYShanLShenEChenRPengT. Over-expression of calpastatin inhibits calpain activation and attenuates myocardial dysfunction during endotoxaemia. Cardiovasc Res 2009;83:72–7919318376
  • LiYArnoldJMPampilloMBabwahAVPengT. Taurine prevents cardiomyocyte death by inhibiting NADPH oxidase-mediated calpain activation. Free Radic Biol Med 2009;46:51–6118950702
  • LiYLiYFengQArnoldMPengT. Calpain activation contributes to hyperglycaemia-induced apoptosis in cardiomyocytes. Cardiovasc Res 2009;84:100–11019505932
  • ChenMWonDJKrajewskiSGottliebRA. Calpain and mitochondria in ischemia/reperfusion injury. J Biol Chem 2002;277:29181–2918612042324
  • KhalilPNNeuhofCHussR. Calpain inhibition reduces infarct size and improves global hemodynamics and left ventricular contractility in a porcine myocardial ischemia/reperfusion model. Eur J Pharmacol 2005;528:124–13116324693
  • ManiSKBalasubramanianSZavadzkasJA. Calpain inhibition preserves myocardial structure and function following myocardial infarction. Am J Physiol Heart Circ Physiol 2009;297:H1744–H175119734364
  • WilkinsBJDaiYSBuenoOF. Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy. Circ Res 2004;94:110–11814656927
  • BourajjajMArmandASda Costa MartinsPA. NFATc2 is a necessary mediator of calcineurin-dependent cardiac hypertrophy and heart failure. J Biol Chem 2008;283:22295–2230318477567
  • ColellaMGrisanFRobertVTurnerJDThomasAPPozzanT. Ca2+ oscillation frequency decoding in cardiac cell hypertrophy: role of calcineurin/NFAT as Ca2+ signal integrators. Proc Natl Acad Sci USA 2008;105:2859–286418287024
  • YangDMaSTanY. Increased expression of calpain and elevated activity of calcineurin in the myocardium of patients with congestive heart failure. Int J Mol Med 2010;26:159–16420514436
  • TanYDourdinNWuCDe VeyraTElceJSGreerPA. Conditional disruption of ubiquitous calpains in the mouse. Genesis 2006;44:297–30316783822
  • AbelEDKaulbachHCTianR. Cardiac hypertrophy with preserved contractile function after selective deletion of GLUT4 from the heart. J Clin Invest 1999;104:1703–171410606624
  • BasheyRIDonnellyMInsingaFJimenezSA. Growth properties and biochemical characterization of collagens synthesized by adult rat heart fibroblasts in culture. J Mol Cell Cardiol 1992;24:691–7001404409
  • LiJZhuHShenEWanLArnoldJMPengT. Deficiency of rac1 blocks NADPH oxidase activation, inhibits endoplasmic reticulum stress, and reduces myocardial remodeling in a mouse model of type 1 diabetes. Diabetes 2010;59:2033–204220522592
  • DourdinNBhattAKDuttP. Reduced cell migration and disruption of the actin cytoskeleton in calpain-deficient embryonic fibroblasts. J Biol Chem 2001;276:48382–4838811602605
  • PengTLuXLeiMMoeGWFengQ. Inhibition of p38 MAPK decreases myocardial TNF-alpha expression and improves myocardial function and survival in endotoxemia. Cardiovasc Res 2003;59:893–90014553829
  • PengTZhangTLuXFengQ. JNK1/c-fos inhibits cardiomyocyte TNF-alpha expression via a negative crosstalk with ERK and p38 MAPK in endotoxaemia. Cardiovasc Res 2009;81:733–74119043087
  • van RooijEDoevendansPAde TheijeCCBabikerFAMolkentinJDde WindtLJ. Requirement of nuclear factor of activated T-cells in calcineurin-mediated cardiomyocyte hypertrophy. J Biol Chem 2002;277:48617–4862612226086
  • LiYHaTGaoX. NF-kappaB activation is required for the development of cardiac hypertrophy in vivo. Am J Physiol Heart Circ Physiol 2004;287:H1712–H172015142841
  • WilkinsBJDaiYSBuenoOF. Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy. Circ Res 2004;94:110–11814656927
  • ZelarayanLRengerANoackC. NF-kappaB activation is required for adaptive cardiac hypertrophy. Cardiovasc Res 2009;84:416–42419620128
  • ChenFLuYKuhnDC. Calpain contributes to silica-induced I kappa B-alpha degradation and nuclear factor-kappa B activation. Arch Biochem Biophys 1997;342:383–3889186501
  • AsbunJVillarrealFJ. The pathogenesis of myocardial fibrosis in the setting of diabetic cardiomyopathy. J Am Coll Cardiol 2006;47:693–70016487830
  • WilsonEMSpinaleFG. Myocardial remodelling and matrix metalloproteinases in heart failure: turmoil within the interstitium. Ann Med 2001;33:623–63411817657
  • TaegtmeyerHMcNultyPYoungME. Adaptation and maladaptation of the heart in diabetes: Part I: general concepts. Circulation 2002;105:1727–173311940554
  • McKinseyTAKassDA. Small-molecule therapies for cardiac hypertrophy: moving beneath the cell surface. Nat Rev Drug Discov 2007;6:617–63517643091
  • LetavernierEPerezJBellocqA. Targeting the calpain/calpastatin system as a new strategy to prevent cardiovascular remodeling in angiotensin II-induced hypertension. Circ Res 2008;102:720–72818258859
  • GuptaSYoungDMaitraRK. Prevention of cardiac hypertrophy and heart failure by silencing of NF-kappaB. J Mol Biol 2008;375:637–64918037434
  • Van der HeidenKCuhlmannSLuongAZakkarMEvansPC. Role of nuclear factor kappaB in cardiovascular health and disease. Clin Sci (Lond) 2010;118:593–60520175746
  • HeidrichFMEhrlichBE. Calcium, calpains, and cardiac hypertrophy: a new link. Circ Res 2009;104:e19–e2019179660
  • TakedaNManabeIUchinoY. Cardiac fibroblasts are essential for the adaptive response of the murine heart to pressure overload. J Clin Invest 2010;120:254–26520038803
  • Hamid T, Guo SZ, Kingery JR, Xiang X, Dawn B, Prabhu SD. Cardiomyocyte NF-kappaB p65 promotes adverse remodeling, apoptosis and endoplasmic reticulum stress in heart failure. Cardiovasc Res 2011;89:129–138
  • OnaiYSuzukiJMaejimaY. Inhibition of NF-kappaB improves left ventricular remodeling and cardiac dysfunction after myocardial infarction. Am J Physiol Heart Circ Physiol 2007;292:H530–H53816920808
  • PetrovVVFagardRHLijnenPJ. Stimulation of collagen production by transforming growth factor-beta1 during differentiation of cardiac fibroblasts to myofibroblasts. Hypertension 2002;39:258–26311847194
  • CampTMTyagiSCSeniorRMHaydenMRTyagiSC. Gelatinase B(MMP-9) an apoptotic factor in diabetic transgenic mice. Diabetologia 2003;46:1438–144512928773
  • WestermannDRutschowSJägerS. Contributions of inflammation and cardiac matrix metalloproteinase activity to cardiac failure in diabetic cardiomyopathy: the role of angiotensin type 1 receptor antagonism. Diabetes 2007;56:641–64617327431
  • YarasNSariahmetogluMBilginogluA. Protective action of doxycycline against diabetic cardiomyopathy in rats. Br J Pharmacol 2008;155:1174–118418806806
  • MoshalKSSinghMSenU. Homocysteine-mediated activation and mitochondrial translocation of calpain regulates MMP-9 in MVEC. Am J Physiol Heart Circ Physiol 2006;291:H2825–H283516877562